Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
复制标题
DOI：
10.1259/bjr.20160560
复制
发表时间：
2016-12
期刊：
影响因子：
--
通讯作者：
Sasaki R
中科院分区：
文献类型：
--
作者：
Nakamura M;Nishimura H;Nakayama M;Mayahara H;Uezono H;Harada A;Hashimoto N;Ejima Y;Ishihara T;Sasaki R
本研究的目的是调查射波刀肺立体定向体部放疗（SBRT）后症状性放射性肺炎（RP）的发生率，并评估症状性RP的预测因素。使用CyberKnife® VSI ™系统（Accuracy Inc.，桑尼维尔，CA）在2013年5月至2015年9月之间。总辐射剂量范围为48至56戈伊，分四次均等照射。症状RP定义为≥ 2级。使用单变量和多变量分析评估症状性RP的预测因素。中位随访时间为12.5个月（范围：3 - 27个月），在56例患者中的6例（10.7%）中观察到症状性RP。在单变量分析中，肺活量百分比（p <0.05），最大肿瘤直径（p <0.05），大体肿瘤体积（p <0.05），计划靶体积（P <0.01），平均肺剂量（p <0.01）和接受5 - 50戈伊辐射的正常肺体积（V5 - 50）（p <0.01）被确定为有症状RP的显著预测因素。在多变量分析中，只有V25> 3.4%（p = 0.011）被确定为有症状RP的显著预测因素。射波刀SBRT后症状性RP的发生率与基于线性加速器的SBRT中报告的发生率几乎相同。观察到V25> 3.4%与发生症状性RP的风险之间存在显著相关性。这是第一份研究射波刀SBRT治疗肺癌后症状性RP预后因素的报告。新开发的评分系统可能有助于预测症状性RP。
The aims of this study were to investigate the frequency of symptomatic radiation pneumonitis (RP) after CyberKnife lung stereotactic body radiotherapy (SBRT) and to evaluate predictive factors of symptomatic RP. 56 patients with peripheral non-small-cell lung cancer were treated using the CyberKnife® VSI™ System (Accuracy Inc., Sunnyvale, CA) between May 2013 and September 2015. Total radiation doses ranged from 48 to 56 Gy, as delivered in four equal fractions. Symptomatic RP was defined as a grade of ≥2. Predictive factors for symptomatic RP were evaluated using univariate and multivariate analyses. With a median follow-up duration of 12.5 months (range, 3–27 months), symptomatic RP was observed in 6 (10.7%) of the 56 patients. In the univariate analysis, percent vital capacity (p < 0.05), maximum tumour diameter (p < 0.05), gross tumour volume (p < 0.05), planning target volume (p < 0.01), mean lung dose (p < 0.01) and a normal lung volume receiving 5–50 Gy of radiation (V5–50) (p < 0.01) were identified as significant predictive factors for symptomatic RP. In the multivariate analysis, only a V25 >3.4% (p = 0.011) was identified as a significant predictive factor of symptomatic RP. The incidence of symptomatic RP after CyberKnife SBRT was almost identical to the incidences reported in the linear accelerator-based SBRT. A significant association was observed between a V25 >3.4% and the risk of developing symptomatic RP. This is the first report that has investigated prognostic factors for symptomatic RP after CyberKnife SBRT for lung cancer. The newly developed scoring system may help to predict symptomatic RP.
登录
查看更多内容
影响因子：
51.1
作者：
Chang, Joe Y.;Senan, Suresh;Paul, Marinus A.;Mehran, Reza J.;Louie, Alexander V.;Balter, Peter;Groen, Harry J. M.;McRae, Stephen E.;Widder, Joachim;Feng, Lei;van den Borne, Ben E. E. M.;Munsell, Mark F.;Hurkmans, Coen;Berry, Donald A.;van Werkhoven, Erik;Kresl, John J.;Dingemans, Anne-Marie;Dawood, Omar;Haasbeek, Cornelis J. A.;Carpenter, Larry S.;De Jaeger, Katrien;Komaki, Ritsuko;Slotman, Ben J.;Smit, Egbert F.;Roth, Jack A.
通讯作者：
Roth, Jack A.
影响因子：
3.4
作者：
Shen, Ze-Tian;Wu, Xin-Hu;Zhu, Xi-Xu
通讯作者：
Zhu, Xi-Xu
影响因子：
5.7
作者：
van Zyp, Noelle C. van der Voort;Prevost, Jean-Briac;Nuyttens, Joost J.
通讯作者：
Nuyttens, Joost J.
DOI：
10.1016/j.ijrobp.2012.03.041
发表时间：
2013-01-01
影响因子：
7
作者：
Baker, Ryan;Han, Gang;Dilling, Thomas J.
通讯作者：
Dilling, Thomas J.
影响因子：
20.4
作者：
Onishi, Hiroshi;Shirato, Hiroki;Araki, Tsutomu
通讯作者：
Araki, Tsutomu